SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 20, 2014
WRIGHT MEDICAL GROUP, INC.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction
|1023 Cherry Road, Memphis, Tennessee
|(Address of principal executive offices)
Registrants telephone number, including area code: (901) 867-9971
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On August 20, 2014, Wright Medical Group, Inc. (including its subsidiaries, the
Company) announced that Eric Stookey, President, Extremities/Biologics, would cease to be an employee of the Company effective August 20, 2014. Pascal E.R. Girin, the Companys Executive Vice President and Chief Operating
Officer, will assume direct oversight of the Companys extremities and biologics businesses, while the Company conducts a search process to fill the position.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: August 20, 2014
By: /s/ Lance A. Berry
Lance A. Berry
Senior Vice President & Chief Financial Officer